Literature DB >> 3254101

Neuroblastoma--when are urinary catecholamines and their metabolites 'normal'?

D J Worthington1, E M Hammond, B B Eldeeb, A Green, G M Addison, P H Jones, J R Mann.   

Abstract

The overproduction of catecholamines and their metabolites is a well recognised feature of neuroblastoma. Published data are scarce for their urinary excretion in children with neuroblastoma and in ill children in whom this diagnosis may be considered. We have determined a graphical upper reference limit for total catecholamines, total metadrenalines and HMMA in urine, expressed as a ratio to the creatinine concentration, for a group of 174 children with neuroblastoma and 704 hospitalised children with other disorders. This graph has been determined by examining the overlap region between the results for the two groups of children and avoids the irregularities caused by statistical outliers. The sensitivity and specificity of the individual tests indicate that total catecholamines is marginally the best single test to perform when trying to diagnose neuroblastoma, with the best clinical sensitivity being achieved by examining both total catecholamines and HMMA. Only two of the 174 children with neuroblastoma would not have been detected using these two tests. Total metadrenalines did not appear to add any further information and could be dropped from the repertoire in favour of the other two measurements.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3254101     DOI: 10.1177/000456328802500604

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  2 in total

1.  ACP Broadsheet No 127: April 1991. Measurement of catecholamines and their metabolites in urine.

Authors:  C Weinkove
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

Review 2.  Is neuroblastoma screening evaluation needed and feasible?

Authors:  J Estève; L Parker; P Roy; F Herrmann; S Duffy; D Frappaz; C Lasset; C Hill; H Sancho-Garnier; J Michaelis
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.